Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

ACADIA Pharma's Shares Open 75% Higher on Positive Anti-Psychosis Drug Phase 3 Results

Shares of ACADIA Pharmaceuticals opened up 75% higher today after the company announced that its Phase 3 Study of pimavanserin for the treatment of dementia-related psychosis met its primary endpoint. San Diego, Calif.-based biopharmaceutical company ACADIA Pharmaceu...
Streetwise Reports | September 10, 2019 |

Karuna Shares Jump 375% Higher on Phase 2 Acute Psychosis Treatment Trial Data

Shares of Karuna Therapeutics, which completed an IPO in July 2019, soared more than 375% higher today after the firm reported that its KarXT met primary endpoint in a phase 2 clinical trial of acute psychosis in patients with schizophrenia. This morning clinical-stag...
Streetwise Reports | November 19, 2019 |

Myovant Sciences Shares Rise on NDA Filing for Uterine Fibroid Combination Therapy Drug

Shares of Myovant Sciences traded 40% higher after the company reported that it has submitted a New Drug Application to the FDA for once-daily relugolix combination tablet for the treatment of women with uterine fibroids. Healthcare company Myovant Sciences Ltd. (...
Streetwise Reports | June 2, 2020 |

Buzz on the Bullboards: The calm before another September rally?

It’s the last leg of what looks like an end-of-month rally as investors try to make the most of August’s losses. Traders are neck-deep into a data-heavy week from company fiscal reports that could chart the hike path for interest rates. ...
Jonathon Brown | August 31, 2023 |

An Emerging Medical Market Play with Great Opportunity

(Image via Bioasis Technologies Inc.) Biopharmaceutical Company Bioasis Technologies Inc. ( TSX-V: BTI , OTCQB: BIOAF , Forum ) is developing its proprietary xB 3TM platform technology to deliver therapeutics across the blood brain barrier (BBB) and int...
Stockhouse Editorial | July 28, 2020 |

Flying Under the Radar with a Possible COVID-19 Treatment

Investors would think a pharmaceutical company heading into Phase 2b/3 human trials for treating the third most malignant disease after lung cancer and pancreatic cancer would draw eyes from major players. If that same company announced it was embarking on Phase2b/3 human tri...
Stockhouse Editorial | September 8, 2020 |

Allakos Shares Double on AK002 Phase 2 Results and Earnings

Allakos Inc. shares are soaring today as the company reported Q2/19 earnings and announced positive results from its phase 2 study for its AK002 inhibitor used in the treatment of eosinophil and mast cell related diseases. Clinical stage biotech company Allak...
Streetwise Reports | August 7, 2019 |

Myovant Sciences Shares Up 110% on Phase 3 Advanced Prostate Cancer Data

Shares of Myovant Sciences opened 120% higher today after the firm reported a 97% response rate in its Phase 3 HERO Study of oral Relugolix in men with advanced prostate cancer. In the study, Relugolix achieved all six key secondary endpoints and the firm expects to submit a N...
Streetwise Reports | November 20, 2019 |

Cassava Sciences' Shares Trade Up 20% on Updated Phase 2a Alzheimer's Data

Shares of Cassava Sciences traded 20% higher after the firm presented additional data from the Phase 2a study of its investigational drug candidate PTI-125 for Alzheimer's disease to the Clinical Trials on Alzheimer's Disease conference in San Diego, Calif. Neurodegen...
Streetwise Reports | December 9, 2019 |

iBio Shares Trade Up 40% After Announcing Development of Proprietary COVID-19 Vaccine Candidates

iBio Inc. shares traded higher after the company reported that it has filed several provisional patents for its SARS-CoV-2 Virus-Like Particle platform with the U.S. Patent and Trademark Office. Biologics contract manufacturing firm iBio Inc. (IBIO:NYSE.Ame...
Streetwise Reports | March 19, 2020 |
1 2